We are analyzing https://link.springer.com/article/10.1007/s002800050850.

Title:
Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma | Cancer Chemotherapy and Pharmacology
Description:
Purpose: Jasplakinolide is a novel natural product anticancer agent which acts by inducing over-polymerization of actin. The aim of the current study was to explore the activity of jasplakinolide with hyperthermia and radiation. Methods: The response of human PC-3 and DU-145 prostate carcinoma cells and DU-145 xenografts and the response of the Lewis lung carcinoma to jasplakinolide were studied. Results: Jasplakinolide was cytotoxic toward human prostate carcinoma cells, DU-145, PC-3 and LNCaP in culture, killing 1 log of cells with 0.8, 0.3 and 0.07 m of drug in 24 h, respectively. The combination of jasplakinolide and hyperthermia resulted in primarily additive cell killing by the two modalities in the three prostate carcinoma lines. In combination with radiation, jasplakinolide produced some diminution in the shoulder of the survival curve of normally oxygenated PC-3 cells and was a radiation sensitizer of hypoxic DU-145 cells and hypoxic PC-3 cells. In vivo, jasplakinolide was an active antitumor agent against the Lewis lung carcinoma and the DU-145 prostate carcinoma xenograft. Jasplakinolide was a radiation sensitizer in the Lewis lung carcinoma. Jasplakinolide was also effective against the systemic Lewis lung carcinoma, decreasing lung metastases. Lung metastases were further decreased when jasplakinolide was administered along with radiation to the subcutaneous primary tumor. In the DU-145 tumor, the effects of jasplakinolide and fractionated radiation for 1 or 2 weeks appeared to be primarily additive. Conclusion: Jasplakinolide is an interesting new anticancer agent for which further study both as an anticancer agent and in combined modality regimens is warranted.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Non-Profit & Charity
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

jasplakinolide, carcinoma, article, radiation, cancer, prostate, lung, cells, access, lewis, privacy, cookies, content, hyperthermia, information, log, publish, search, human, agent, open, data, journal, research, chemotherapy, takeuchi, ara, sausville, explore, anticancer, hypoxic, discover, usa, springer, optional, personal, parties, policy, find, track, pharmacology, interaction, cite, hideya, gulshan, edward, beverly, teicher, study, response,

Topics {✒️}

article cancer chemotherapy month download article/chapter national cancer institute human prostate carcinoma prostate carcinoma lines related subjects lewis lung carcinoma privacy choices/manage cookies full article pdf radiation therapy decreasing lung metastases check access instant access hypoxic du-145 cells oxygenated pc-3 cells european economic area combined modality regimens hypoxic pc-3 cells active antitumor agent conditions privacy policy subcutaneous primary tumor cancer treatment accepting optional cookies gulshan ara article takeuchi journal finder publish article log du-145 xenografts lung metastases hideya takeuchi article cite primarily additive privacy policy explore personal data books a anticancer agent radiation sensitizer fractionated radiation human pc-3 killing 1 log du-145 tumor optional cookies manage preferences hyperthermia resulted subscription content similar content information data protection hypoxic stress

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma
         description: Purpose: Jasplakinolide is a novel natural product anticancer agent which acts by inducing over-polymerization of actin. The aim of the current study was to explore the activity of jasplakinolide with hyperthermia and radiation. Methods: The response of human PC-3 and DU-145 prostate carcinoma cells and DU-145 xenografts and the response of the Lewis lung carcinoma to jasplakinolide were studied. Results: Jasplakinolide was cytotoxic toward human prostate carcinoma cells, DU-145, PC-3 and LNCaP in culture, killing 1 log of cells with 0.8, 0.3 and 0.07 m of drug in 24 h, respectively. The combination of jasplakinolide and hyperthermia resulted in primarily additive cell killing by the two modalities in the three prostate carcinoma lines. In combination with radiation, jasplakinolide produced some diminution in the shoulder of the survival curve of normally oxygenated PC-3 cells and was a radiation sensitizer of hypoxic DU-145 cells and hypoxic PC-3 cells. In vivo, jasplakinolide was an active antitumor agent against the Lewis lung carcinoma and the DU-145 prostate carcinoma xenograft. Jasplakinolide was a radiation sensitizer in the Lewis lung carcinoma. Jasplakinolide was also effective against the systemic Lewis lung carcinoma, decreasing lung metastases. Lung metastases were further decreased when jasplakinolide was administered along with radiation to the subcutaneous primary tumor. In the DU-145 tumor, the effects of jasplakinolide and fractionated radiation for 1 or 2 weeks appeared to be primarily additive. Conclusion: Jasplakinolide is an interesting new anticancer agent for which further study both as an anticancer agent and in combined modality regimens is warranted.
         datePublished:
         dateModified:
         pageStart:491
         pageEnd:496
         sameAs:https://doi.org/10.1007/s002800050850
         keywords:
            Key words Jasplakinolide
            Hyperthermia
            Radiation sensitization
            Prostate cancer
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:42
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Hideya Takeuchi
               affiliation:
                     name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
                     address:
                        name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gulshan Ara
               affiliation:
                     name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
                     address:
                        name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Edward A. Sausville
               affiliation:
                     name:Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
                     address:
                        name:Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Beverly Teicher
               affiliation:
                     name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
                     address:
                        name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma
      description: Purpose: Jasplakinolide is a novel natural product anticancer agent which acts by inducing over-polymerization of actin. The aim of the current study was to explore the activity of jasplakinolide with hyperthermia and radiation. Methods: The response of human PC-3 and DU-145 prostate carcinoma cells and DU-145 xenografts and the response of the Lewis lung carcinoma to jasplakinolide were studied. Results: Jasplakinolide was cytotoxic toward human prostate carcinoma cells, DU-145, PC-3 and LNCaP in culture, killing 1 log of cells with 0.8, 0.3 and 0.07 m of drug in 24 h, respectively. The combination of jasplakinolide and hyperthermia resulted in primarily additive cell killing by the two modalities in the three prostate carcinoma lines. In combination with radiation, jasplakinolide produced some diminution in the shoulder of the survival curve of normally oxygenated PC-3 cells and was a radiation sensitizer of hypoxic DU-145 cells and hypoxic PC-3 cells. In vivo, jasplakinolide was an active antitumor agent against the Lewis lung carcinoma and the DU-145 prostate carcinoma xenograft. Jasplakinolide was a radiation sensitizer in the Lewis lung carcinoma. Jasplakinolide was also effective against the systemic Lewis lung carcinoma, decreasing lung metastases. Lung metastases were further decreased when jasplakinolide was administered along with radiation to the subcutaneous primary tumor. In the DU-145 tumor, the effects of jasplakinolide and fractionated radiation for 1 or 2 weeks appeared to be primarily additive. Conclusion: Jasplakinolide is an interesting new anticancer agent for which further study both as an anticancer agent and in combined modality regimens is warranted.
      datePublished:
      dateModified:
      pageStart:491
      pageEnd:496
      sameAs:https://doi.org/10.1007/s002800050850
      keywords:
         Key words Jasplakinolide
         Hyperthermia
         Radiation sensitization
         Prostate cancer
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:42
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Hideya Takeuchi
            affiliation:
                  name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
                  address:
                     name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gulshan Ara
            affiliation:
                  name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
                  address:
                     name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Edward A. Sausville
            affiliation:
                  name:Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
                  address:
                     name:Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Beverly Teicher
            affiliation:
                  name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
                  address:
                     name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:42
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
      address:
         name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
         type:PostalAddress
      name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
      address:
         name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
         type:PostalAddress
      name:Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
      address:
         name:Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, , US
         type:PostalAddress
      name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
      address:
         name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Hideya Takeuchi
      affiliation:
            name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
            address:
               name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
               type:PostalAddress
            type:Organization
      name:Gulshan Ara
      affiliation:
            name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
            address:
               name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
               type:PostalAddress
            type:Organization
      name:Edward A. Sausville
      affiliation:
            name:Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
            address:
               name:Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, , US
               type:PostalAddress
            type:Organization
      name:Beverly Teicher
      affiliation:
            name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA
            address:
               name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
      name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
      name:Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, , US
      name:Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, 44 Binney St., Boston, MA 02115, USA, , US
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(31)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.07s.

LINK . SPRINGER . COM {}